HK Stock Market Move | FANGZHOU JIANKE (06086) rose more than 10% intraday; the company's case was selected as an outstanding practice for high-quality development of pharmaceutical distribution in 2026.

FANGZHOU JIANKE (06086) rose more than 10% intraday, hitting a high of HK$1.03, a new high since June. As of press time, it was up 5.88% at HK$0.99. Recently, the 10th Yuncheng Tianyu Conference Pharmaceutical Distribution Review and Certification Technology Conference, themed "New Order New Ecosystem, Coexistence of Regulation and Value," was held in Guangzhou. At the conference, FANGZHOU JIANKE's case "AI Algorithm-Based Pharmaceutical Procurement Inventory Collaboration Digital-Intelligent Platform Practice" was successfully selected for the compilation, and this selection further confirms the industry demonstration value of the company's AI digital-intelligent practices. With the Xingshi large model as its technology foundation, the company has built a series of "AI + chronic disease services" digital-intelligent solutions adapted to different service scenarios; at the same time, it has accelerated the implementation of digital-intelligent tools, relying on the AI health steward and AI medication assistant to optimize the user experience. It is worth noting that in the first half of the year, FANGZHOU JIANKE's revenue reached RMB1.8245 billion, up 22.2% year on year; adjusted net profit reached RMB18.708 million, up 6.4% year on year, maintaining a good momentum of sustained profitability. With its extensive and professional resources of registered physicians, the company has built a medical service network covering multiple departments; its supply chain network covers more than 1,800 suppliers and more than 1,000 pharmaceutical manufacturers, and economies of scale are gradually emerging. In the first half of 2026, FANGZHOU JIANKE's paid user repurchase rate reached as high as 89.2%.